PIG3 microsatellite alleles were also analyzed using paired diagnosis and remission samples in 85 patients. Leukemic infiltration at diagnosis was always greater than 65% and remission samples (peripheral blood) had less that 1% of abnormal myeloid population assessed by flow cytometry. In four cases, a loss of heterozygosity (LOH) of the microsatellite in the PIG3 promoter was detected ( Figure 1 ) (4.7%): three patients displayed a normal karyotype without 2p alterations and the remaining patient had a del 16(q25). One patient disclosed an FLT3 internal tandem duplication (ITD) and two showed a MLL rearrangement of the self-fusion type. All four cases presented a loss of the longer allele and consequently, the most effective in PIG3 induction (Table 1) . No p53 mutations were detected in those cases when exons 5-9 were analyzed.
It has been shown that a higher number of the pentanucleotide repeats correlates with a stronger responsiveness to p53 (4) . If LOH at the polymorphic PIG3 promoter really leads to a lower response to p53, these findings may reflect a selective advantage of the more resistant clone to the induction of apoptosis. Regulatory sequences of certain p53 responsive genes may be a recurrent target of genetic lesions during the leukemogenic process even in cases with a normal karyotype.
It should be investigated whether neoplastic cells with a single copy of the short microsatellite PIG3 promoter show clonal dominance and the mechanisms underlying the microdeletion process.
TNF-a receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells Leukemia (2004) the unique ability to differentiate into leukemic DC, thereby conserving their intrinsic leukemia antigen repertoire and obtaining full potential of antigen presentation. We have shown that DC generated from acute myeloid leukemic (AML) blasts are able to initiate autologous cytotoxic T-cell responses, and thus hold promise for vaccination purposes in a minimal residual disease (MRD) status. 1 In a recently performed phase-I study on CML-DC vaccination in advanced stage chronic myeloid leukemia (CML), we were able to detect strong DTH-responses representing autologous CML-specific T-cell responses. 2 The presence of various cytokines such as GM-CSF, SCF, Flt3-L, TNF-a, IL-3 and IL-4 induces differentiation into AML-DC in approximately 2 weeks, also under clinical grade serum-free The PIG3 polymorphic promoter shows LOH in de novo AML. Electropherograms obtained with labeled PCR products containing the PIG3 microsatellite (TGYCC)n. Top: sample obtained at diagnosis displayed a loss of the 17 repeats allelle (arrow). Bottom: sample obtained at remission. conditions. 1, 3 We showed previously that it is also possible to generate AML-DC in a 2-day culture period by the incubation with calcium ionophores (CI), thereby bypassing receptor mediated signalling.
1 AML-DC cultured by CI displayed, both phenotypically and functionally, a more mature state than those cultured with a combination of cytokines. However, CI-cultured cells were found to be less viable. 1 Consequently, the CI-based method can only be used if high amounts of AML blasts are available. The common use of the cytokine-based method to develop AML-DC is accompanied by a variable DC differentiation inducibility, irrespective of French-American-British (FAB) classification. For these reasons, we examined the possibility to select a culture method in advance that will result in the most optimal generation of AML-DC for each individual patient. In this study we investigated whether the cytokine receptor profile of AML blasts is predictive for the ability to differentiate into AML-DC.
After informed consent, peripheral blood and bone marrow mononuclear cells of AML patients were collected. A total of 33 patients (21 female, 12 male) were included with a median age of 60 years (range: 22-88), with the following FAB classifications: M0 (2), M1 (5), M2 (5), M4 (8), M5 (10), RAEB-t (1), unclassified (2) . AML cells were cultured as published previously. 1, 3 Briefly, fresh or thawed mononuclear cells were cultured in either RPMI-1640; 20% fetal calf serum; 100 U/ml penicillin and 100 mg/ml streptomycin (n ¼ 6) or Stem Spant SFEM serum-free medium (n ¼ 27); 100 U/ml penicillin and 100 mg/ml streptomycin. Differentiation towards DC was induced by the addition of a combination of cytokines (n ¼ 33): GM-CSF, TNF-a, IL-3, SCF, Flt3-L and IL-4 or CI A23187 and IL-4 (n ¼ 28).
1,3 IL-4 was added to the CI culture to prevent the differentiation towards the macrophage lineage. After 14 and 2 days, respectively, cells were harvested. Prior and subsequent to culture phenotypic analysis of the following markers was performed by flowcytometry: CD34, CD14, CD45, CD40, CD54, CD80, CD86, CD83, CD1a and HLA-DR as previously described. 3 Additionally, we analysed AML blasts, identified by gating the CD45 dim population, for the expression of eight cytokine receptors: FITC-labelled GM-CSFR (CD116, Pharmingen, San Diego, CA, USA), TNF-aRI (CD120a, R&D Systems, Minneapolis, MN, USA), PE-labelled Flt3-LR (CD135, Pharmingen), IFN-gR (CD119, Pharmingen), TNF-aRII (CD120b, R&D Systems), IL-3R (CD123, Becton Dickinson, San Jose, CA, USA), IL-4R (CD124, Immunotech, Marseille, France) and APC labelled SCFR (CD117, Becton Dickinson). Results were calculated as percentage positive cells as compared to the appropriate isotype control. Analysis of the results was made using CellQuest software (Becton Dickinson). Apoptotic and necrotic cells, identified by syto-16 and 7-amino-actinomycin (7-AAD) staining, as previously described, were excluded from the analysis. 1 The mean fluorescence index (MFI) was calculated to determine the intensity of marker expression and defined as the ratio of the mean channel peak fluorescence intensity of marker expression of the specific antibody and the mean channel peak fluorescence intensity of its corresponding isotype control. We found that cytokine receptors on AML blasts are heterogeneously expressed: GM-CSFR (median expression %: 54; range: 1-98), SCFR (30; 0-87), IFNg-R (89; 20-99), TNFa-RI (17; 1.0-57), TNFa-RII (8; 0-51), IL-3R (81; 14-98), IL-4R (0; 0-2), Flt-3R (70; 10-99). In Table 1 the phenotype of AML blasts of each individual patient is depicted as well as the percentage of AML-DC after cytokine culture. Phenotypic markers with reported prognostic value, for example, CD34, CD86 and CD14 are shown. 4, 5 As described previously, cultured AML-DC are characterized by an increased expression as well as an increased MFI of the most important DC markers CD40, CD54, CD80, CD86, CD83 and HLA-DR as compared to uncultured blasts. 1, 3 Cells with the DC phenotype were not detected before culture. Viability, determined by syto-16 and 7-AAD staining, and relative AML-DC yield (defined as the number of viable cells after culture divided by the number of viable cells before culture, multiplied by the percentage of CD40 þ cells after culture) were calculated (viability; median: 55%, range: 3-98%, relative yield; median: 22.5 Â 10 6 , range: 0-466 Â 10 6
). In the cytokine culture it was possible in 17/33 (52%) patients, to induce differentiation into AML-DC as evidenced by the upregulation of CD40, CD54, HLA-DR, CD83 and costimulatory molecules CD80 and CD86. In 28/33 patients we cultured AML blasts in the presence of CI, which was successful in 23/28 (82%) patients. These data are in accordance with our previous studies. 1, 3 After the culture of AML-DC, the predictive value of the expression of each cytokine receptor for parameters of culture outcome was determined by multiple regression analysis. TNFa-RI expression on AML blasts revealed to be a strong positive predictor for the percentage expression of CD40 (P ¼ 0.003), CD54 (P ¼ 0.003) and CD86 (P ¼ 0.015) at the end of AML-DC culture. The expression of TNFa-RI was also highly predictive for the MFI of CD54 (P ¼ 0.031), CD86 (Po0.001) and HLA-DR (P ¼ 0.002). No significant positive predictors could be identified among the remaining cytokine receptors. Additionally, TNFa-RI expression correlated significantly with the percentage of CD40 þ /CD86 þ double-positive cells representing the most mature AML-DC (Spearman's r: 0.50; P ¼ 0.003), as well as with the expression of CD40 (0.44; P ¼ 0.01), CD80 (0.40; P ¼ 0.022), CD83 (0.39; P ¼ 0.024) and CD86 (0.53; P ¼ 0.001) as well as the MFI of CD40 (0.44; P ¼ 0.011), CD80 (0.35; P ¼ 0.047), CD86 (0.55; P ¼ 0.001) and HLA-DR (0.40; P ¼ 0.024) at the end of culture. A cutoff value of 15% positivity as compared to the isotype control was chosen in accordance with general guidelines for immunophenotyping of acute leukemia's and is close to the median expression level of Table 1 Phenotype of AML cells before and after cytokine culture Correspondence 17%. The culture of blast cells expressing X15% of TNFa-RI on their membrane resulted in a significant increased expression of CD40 þ /CD86 þ at the end of culture as compared to AML blasts with o15% TNFa-RI expression (Figure 1a) . Similarly, the expression of other DC markers is significantly higher in AML samples expressing X15% TNFa-RI (Figure 1b) . The expression of these markers did not differ between both subgroups prior to culture (Figure 1b) . Incubation of TNFa-RI À AML samples with CI provides an alternative culture method. In 11 AML samples with o15% TNFa-RI expression, the cytokine mix was unable to induce differentiation into AML-DC. However, incubation with CI led to the generation of CD40 þ /CD86 þ AML-DC in 8/11 (73%) of these TNFa-RI À samples. To further study the role of the identified predictor TNFa-RI, the TNFa-RI þ fraction was separated from the TNFa-RI À fraction, according to standard sorting procedures by the use of FACS-Vantage cytometer (Becton Dickinson). For this experiment two patients were selected based on their different TNFa-RI expression (pt 1: 20%, pt 2: 56%) and the proven ability of the nonsorted blast populations to differentiate into AML-DC in the presence of cytokines. Separate cultures of the isolated TNFa-RI þ and TNFa-RI À fractions in the presence of cytokines as described above, resulted in an increased expression of CD40 þ /CD86 þ AML-DC, as well as an increased expression of the other DC markers, in TNFa-RI þ fractions as compared to TNFa-RI À fractions (Figure 2a ). As shown in previous studies, leukemic DC are potent inducers of T cell proliferation. 1, 3 To assess the ability of the cultured AML cells in the TNFa-RI þ and TNFa-RI À fractions, to stimulate allogeneic T cell proliferation a mixed leukocyte reaction (MLR) was performed as described previously. 3 A representative MLR resulted in a two-to three-fold increased T cell stimulatory capacity of the cultured TNFa-RI þ fractions as compared to the cultured TNFa-RI À fractions (Figure 2b ). In control experiments no allostimulatory capacity of uncultured blasts could be shown.
Recently, it was found that the CD14 þ cell population in AML represents the leukemic compartment that can be induced in vitro to a mature DC population in the presence of GM-CSF, IL-4 and CD40L whereas the CD14 À population could not. 4 In Figure 1 (a) X15% TNFa-RI expression on AML blasts results in significant increased expression of CD40 þ /CD86 þ AML-DC at the end of culture as compared to blasts expressing o15% TNFa-RI (P ¼ 0.003). Box-and-whisker plots show in the box the 25th and 75th percentile while the whiskers show the 2.5th and 97.5th percentile. The central line represents the median, the 50th percentile. (b) Box-and-whisker plots show the immunophenotype of AML cells before and after culture with cytokines (N ¼ 33). The patient group is divided into two groups based upon the expression of TNFa-RI on the AML blasts (o15% (N ¼ 16) or X15% (N ¼ 17) ). Differences between uncultured blasts (day 0) and cultured AML-DC are presented, as well as differences in culture outcome between both groups. n, Po0.05; E, P ¼ 0.06; #, P ¼ 0.08. þ /CD86 þ AML-DC was observed (Spearman's r: 0.51, P ¼ 0.002). However, in 5/19 CD14 À AML samples we were able to successfully induce DC differentiation in presence of cytokines. Of these AML samples, 4/5 showed X15% TNFa-RI expression, while 12/14 CD14 À samples, not inducible to AML-DC, showed o15% TNFa-RI expression, pointing towards a possible role for TNFa-RI in CD14 À AML samples. Linear regression analysis showed that an increase of 10% in CD14 expression results in a 2.3% increase of AML-DC percentage at the end of culture, whereas an increase of 10% in TNFa-RI expression results in a 4.6% increase. In a multiple regression analysis both CD14 and TNFa-RI are significant predictors of CD40 þ /CD86 þ AML-DC percentage (P ¼ 0.008 and 0.045, respectively). Importantly, the addition of TNFa-RI to CD14 as established predictor results in a relative increase of 31% of the explained variance in AML-DC culture outcome from R 2 ¼ 29% to R 2 ¼ 38%. TNFa-RI expression solely displays an explained variance of R 2 ¼ 21%.
To study the effect of TNFa-RI expression on CD14 þ and CD14 À blasts in more detail, three leukemic cell fractions CD14 þ /TNFa-RI þ , CD14 À /TNFa-RI þ and CD14 À /TNFa-RI À , were isolated by FACS sorting and were separately cultured in the presence of cytokines. In Figure 3 the development of AML-DC in the CD14 þ /TNFa-RI þ fraction as well as the CD14 À / TNFa-RI þ fraction is shown. The CD14 À /TNFa-RI À fraction remained CD34 þ and CD45 dim and could not be induced into AML-DC. In accordance with the regression analysis explained above, these data could point to a central role of the presence of TNFa-RI on the CD14 À blast population for the differentiation in AML-DC. Our data are supported by the observation that the CD34 þ human myeloid leukemia-derived cell line, MUTZ-3, upon culture downregulates CD34 expression while acquiring TNFa-RI expression, which is followed by the upregulation of CD14. Subsequently, these cells acquire the mature DC phenotype after differentiation induction (Masterson et al, submitted). Therefore, it could be hypothesized that TNFa-RI is an earlier marker for the prediction of AML-DC differentiation inducibility than CD14. Furthermore, the expression of CD86 on AML blasts has been associated with the generation of leukemic DC. 5 It was found that the CD34 þ /CD86 þ subset could be differentiated into leukemic DC in 6 days of culture, especially in CD14 À cases. 5 In our population for both CD86 and CD34 we could not confirm this relation, possibly due to differences in culture periods.
TNF-a is known to exert multiple effects on AML blasts and is particularly involved in the DC maturation pathway by the induction of costimulatory molecules and downregulation of endocytosis mechanisms. TNF-a binds to two specific cell surface receptors. 7 Maturation of primary AML blasts is determined by the sole stimulation of TNFa-RI, supporting our data that TNFa-RI is predictive for mature DC development. 8 In conclusion, we demonstrated that TNFa-RI expression predicts differentiation into leukemic DC and therefore might be useful to select for optimal culture protocols for active specific immunisation in AML. À /TNFa-RI À fraction remained CD34 þ and CD45 dim and could not be induced into AML-DC.
